Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m
The move grants Ligand royalty rights to QARZIBA (dinutuximab beta), a treatment for high-risk neuroblastoma in patients aged 12 months and above.
Cygnus Technologies WP
Dupixent “addresses current gap” in COPD biologics landscape
LOTTE BIOLOGICS breaks ground on biopharma plant in Incheon
Ability Biologics closes extended $18m seed funding round
Kyowa Kirin invests $530m in new US biologics manufacturing facility
Bio-Sourcing and Afrigen Biologics partner on biomanufacturing platform
Aurigene Pharmaceutical opens biologics facility in Hyderabad, India
Sanofi to make €1bn biomanufacturing investment in France
